HR5415-119

What This Bill Does

The Nitazene Control Act of 2025 responds to synthetic opioids that can exceed fentanyl potency and have appeared in the illicit drug supply. The findings say DEA has temporarily or permanently scheduled multiple 2-benzylbenzimidazole opioid compounds because of high abuse potential and no accepted medical use, and that class-wide scheduling is needed to address new analogs. The bill adds nitazenes to Schedule I of the Controlled Substances Act as 2-benzylbenzimidazole opioids, covering isomers, esters, ethers, salts, and specified structural variations at the 1-position, 2-position, phenyl portion, and 6-position, so long as the substance exhibits agonist activity at the mu-opioid receptor. It names examples such as etonitazene, clonitazene, metonitazene, isotonitazene, protonitazene, butonitazene, etodesnitazene, flunitazene, N-pyrrolidino etonitazene, N-desethyl isotonitazene, and N-piperidinyl etonitazene. Any covered substance temporarily scheduled under Controlled Substances Act section 201(h) becomes permanently scheduled on enactment. The bill does not authorize new research without proper registration and scheduling compliance.

Who Benefits and How

Drug Enforcement Administration diversion investigators benefit from class-wide Schedule I coverage for nitazenes and analogs. Public health agencies benefit from a permanent federal control framework for emerging synthetic opioid compounds. Families affected by opioid overdoses benefit indirectly if scheduling reduces illicit nitazene proliferation. Registered Schedule I researchers benefit from clarification that research pathways remain available only with proper registration and compliance.

Who Bears the Burden and How

Illicit opioid traffickers face higher federal enforcement risk for nitazenes and covered analogs. Chemical suppliers handling covered compounds must comply with Schedule I registration and control requirements. Researchers without Schedule I registration may not initiate new nitazene research under the bill. DEA scheduling staff must administer permanent class-wide nitazene controls.

Key Provisions

• Adds 2-benzylbenzimidazole opioids commonly known as nitazenes to Schedule I.
• Covers isomers, esters, ethers, salts, structural modifications, and mu-opioid receptor agonist activity.
• Makes temporarily scheduled covered substances permanently scheduled as of enactment.
• Names examples including etonitazene, metonitazene, isotonitazene, protonitazene, and flunitazene.
• Requires proper registration and scheduling compliance for research.